Adage Capital Partners Portfolio holdings
AUM
$59.3B
1-Year Return
26.26%
This Quarter Return
+5.25%
1 Year Return
+26.26%
3 Year Return
+130.73%
5 Year Return
+248.99%
10 Year Return
+658.76%
AUM
$57.2B
AUM Growth
+$551M
(+0.97%)
Cap. Flow
-$296M
Cap. Flow
% of AUM
-0.52%
Top 10 Holdings %
Top 10 Hldgs %
31.76%
Holding
1,007
New
143
Increased
295
Reduced
385
Closed
137
Top Buys
| 1 |
ConocoPhillips
COP
|
$230M |
| 2 |
Bristol-Myers Squibb
BMY
|
$185M |
| 3 |
WESCO International
WCC
|
$171M |
| 4 |
Gilead Sciences
GILD
|
$158M |
| 5 |
Delta Air Lines
DAL
|
$148M |
Top Sells
| 1 |
MRO
Marathon Oil Corporation
MRO
|
$221M |
| 2 |
3M
MMM
|
$154M |
| 3 |
Marsh & McLennan
MMC
|
$115M |
| 4 |
Johnson & Johnson
JNJ
|
$99M |
| 5 |
Novo Nordisk
NVO
|
$94.6M |
Sector Composition
| 1 | Technology | 29.09% |
| 2 | Healthcare | 13.87% |
| 3 | Financials | 11.48% |
| 4 | Consumer Discretionary | 10.65% |
| 5 | Industrials | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
701
CG Oncology
CGON
$2.52B
| $5.74M | 0.01% |
200,000
-200,000
| -50% | -$5.74M |
|
702
Shattuck Labs
STTK
$74.2M
| $5.66M | 0.01% |
4,675,000
+1,775,000
| +61% | +$2.15M |
|
703
Fox Class B
FOX
$24.9B
| $5.64M | 0.01% |
123,265
-1,100
| -0.9% | -$50.3K |
|
704
Cardiff Oncology
CRDF
$144M
| $5.61M | 0.01% |
+1,292,308
| New | +$5.61M |
|
|
SILA
705
Sila Realty Trust, Inc.
SILA
$1.4B
| $5.59M | 0.01% |
230,000
+115,969
| +102% | +$2.82M |
|
706
C4 Therapeutics
CCCC
$194M
| $5.58M | 0.01% |
1,550,000
+1,030,000
| +198% | +$3.71M |
|
707
Erie Indemnity
ERIE
$17.5B
| $5.48M | 0.01% |
13,300
-10,200
| -43% | -$4.2M |
|
708
Five Star Bancorp
FSBC
$702M
| $5.48M | 0.01% |
182,059
+12,214
| +7% | +$368K |
|
709
HBT Financial
HBT
$828M
| $5.42M | 0.01% |
247,692
-17,604
| -7% | -$386K |
|
710
Arbutus Biopharma
ABUS
$805M
| $5.4M | 0.01% |
1,650,941
-1,250,000
| -43% | -$4.09M |
|
711
Immunome
IMNM
$916M
| $5.31M | 0.01% |
500,000
+280,000
| +127% | +$2.97M |
|
712
California Resources
CRC
$4.1B
| $5.19M | 0.01% |
100,000
-50,000
| -33% | -$2.59M |
|
713
Fox Class A
FOXA
$27.4B
| $5.18M | 0.01% |
106,619
-105,100
| -50% | -$5.11M |
|
714
Albemarle
ALB
$9.6B
| $5.15M | 0.01% |
59,779
-83,000
| -58% | -$7.14M |
|
715
Ralph Lauren
RL
$18.9B
| $5.11M | 0.01% |
+22,126
| New | +$5.11M |
|
716
Axsome Therapeutics
AXSM
$6.25B
| $5.08M | 0.01% |
60,000
-465,000
| -89% | -$39.3M |
|
|
RVNC
717
DELISTED
Revance Therapeutics, Inc.
RVNC
| $5.03M | 0.01% |
1,653,689
+603,689
| +57% | +$1.84M |
|
718
Dick's Sporting Goods
DKS
$17.7B
| $4.92M | 0.01% |
+21,500
| New | +$4.92M |
|
719
Stock Yards Bancorp
SYBT
$2.34B
| $4.89M | 0.01% |
+68,300
| New | +$4.89M |
|
720
Algoma Steel
ASTL
$538M
| $4.89M | 0.01% |
500,000
+200,000
| +67% | +$1.96M |
|
|
CNR
721
Core Natural Resources, Inc.
CNR
$3.89B
| $4.8M | 0.01% |
45,000
+13,000
| +41% | +$1.39M |
|
|
DRUG
722
Bright Minds Biosciences
DRUG
$299M
| $4.77M | 0.01% |
+132,500
| New | +$4.77M |
|
723
Lifezone Metals
LZM
$365M
| $4.69M | 0.01% |
674,854
| – | – |
|
724
PENN Entertainment
PENN
$2.99B
| $4.6M | 0.01% |
+232,253
| New | +$4.6M |
|
725
Carlyle Group
CG
$23.1B
| $4.52M | 0.01% |
+89,600
| New | +$4.52M |
|